Rimonabant for the treatment of overweight and obese people.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 3, Issue , 2009, Pages 13-22

  Burch, J ^a   McKenna, C ^b   Palmer, S ^b   Norman, G ^b   Glanville, J ^b   Sculpher, M ^b   Woolacott, N ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

COST BENEFIT ANALYSIS; DRUG EFFECT; ECONOMICS; HUMAN; OBESITY; REVIEW; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; COST-BENEFIT ANALYSIS; HUMANS; OBESITY; OVERWEIGHT; PIPERIDINES; PYRAZOLES; WEIGHT LOSS;

MLCS; MLOWN;

EID: 84857871543     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl3/03     Document Type: Review

References (8)